AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26635229 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention (diet and physical activity)
Number of subjects: 438
Study 26635229 — intervention group
Group type: COMPARATOR
Intervention: PA only group (Happy 10 program)
Number of subjects: 438
Study 26635229 — intervention group
Group type: COMPARATOR
Intervention: Diet only group (nutrition education program)
Number of subjects: 438
Study 26635229 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 438
Study 23345581 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of DNA vaccine (Advax) plus 1 dose of recombinant modified vaccinia virus Ankara (MVA) (TBC‐M4)
Number of subjects: 32
Study 23345581 — intervention group
Group type: COMPARATOR
Intervention: 3 doses of TBC‐M4 alone
Number of subjects: 32
Study 21138518 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin α (target Hb 9.5 to 11.0 g/dL and 11.5 to 13.0 g/dL)
Number of subjects: 118
Study 21138518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 18640465 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/d
Number of subjects: 173
Study 18640465 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/d
Number of subjects: 173
Study 18640465 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 173
Study 16717516 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure ulcer preventive dressing (PPD)
Number of subjects: 30
Study 16717516 — intervention group
Group type: COMPARATOR
Intervention: Thin-film dressing
Number of subjects: 30
Study 12709347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice a day orally for 7 days)
Number of subjects: 55
Study 12709347 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol (500 mg four times a day orally for 14 days)
Number of subjects: 55
Study 12709347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 55
Study 12709347 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 55
Study 11215006 — intervention group
Group type: EXPERIMENTAL
Intervention: STOMP group (community-based antenatal care)
Number of subjects: 1089
Study 11215006 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard antenatal care)
Number of subjects: 1089
Study 9003953 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alpha‐L‐fucosidase activity
Number of subjects: 151
Study 9003953 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy female patients)
Number of subjects: 151
Study 9003953 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 125
Number of subjects: 151
Study 1469466 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU combined with vincristine intravenously and procarbazine orally, followed by radiation therapy
Number of subjects: 75
Study 1469466 — intervention group
Group type: COMPARATOR
Intervention: Surgery followed by radiation therapy
Number of subjects: 75
Study 6367553 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (10 mg)
Number of subjects: 21
Study 6367553 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 21
Study 29277099 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives up to $320/year for a minimum of 1 year
Number of subjects: 320
Study 29277099 — intervention group
Group type: COMPARATOR
Intervention: Control group (no financial incentives)
Number of subjects: 320
Study 25747947 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (I)
Number of subjects: 92
Study 25747947 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (M)
Number of subjects: 92
Study 25747947 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (N)
Number of subjects: 92
Study 24120857 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild depressive symptoms
Number of subjects: 700
Study 24120857 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate depressive symptoms
Number of subjects: 700
Study 24120857 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe depressive symptoms
Number of subjects: 700
Study 24120857 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptom severity
Number of subjects: 700
Study 21161151 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous feeding tube (PEG tube)
Number of subjects: 27
Study 21161151 — intervention group
Group type: COMPARATOR
Intervention: No PEG tube (non-PEG group)
Number of subjects: 27
Study 21211380 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 2 mg once daily for 8 weeks
Number of subjects: 76
Study 21211380 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 2 mg once daily and Tolterodine 2 mg twice daily for 8 weeks
Number of subjects: 76
Study 19183318 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitative educator talk during the DESMOND self‐management programme
Number of subjects: 0
Study 19183318 — intervention group
Group type: COMPARATOR
Intervention: Didactic educator talk during the DESMOND self‐management programme
Number of subjects: 0
Study 16123895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 16123895 — intervention group
Group type: COMPARATOR
Intervention: Mebeverin
Number of subjects: 120
Study 16123895 — intervention group
Group type: COMPARATOR
Intervention: Dietary treatment (fibre)
Number of subjects: 120
Study 12860783 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice nurse
Number of subjects: 1182
Study 12860783 — intervention group
Group type: COMPARATOR
Intervention: On-call pediatrician
Number of subjects: 1182
Study 12382386 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine (1 ml)
Number of subjects: 132
Study 12382386 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine (2 ml)
Number of subjects: 132
Study 12382386 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine (1 ml)
Number of subjects: 132
Study 12382386 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine (2 ml)
Number of subjects: 132
Study 12382386 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine (2 ml)
Number of subjects: 132
Study 12382386 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (1 ml)
Number of subjects: 132
Study 10220941 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA (group 1, n = 41)
Number of subjects: 80
Study 10220941 — intervention group
Group type: COMPARATOR
Intervention: Balanced anaesthesia (group 2, n = 39)
Number of subjects: 80
Study 10220941 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TIVA and balanced anaesthesia
Number of subjects: 80
Study 7898814 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory M nursing model
Number of subjects: 0
Study 7898814 — intervention group
Group type: COMPARATOR
Intervention: Control groups (three nursing units)
Number of subjects: 0
Study 2135692 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms
Number of subjects: 0
Study 2135692 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 micrograms
Number of subjects: 0
Study 2135692 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 800 micrograms
Number of subjects: 0
Study 2135692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7027892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of metoprolol 100 mg and hydrochlorothiazide 12.5 mg, given as 2 tablets o.m.
Number of subjects: 31
Study 7027892 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 50 mg o.m. monotherapy
Number of subjects: 31
Study 31735245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Group Therapy (CBGT)
Number of subjects: 81
Study 31735245 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 81
Study 31735245 — intervention group
Group type: COMPARATOR
Intervention: Wait-list condition
Number of subjects: 81
Study 29177434 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4547 80 mg twice daily, orally, on a 2 weeks on/1 week off schedule of a 21-day cycle
Number of subjects: 71
Study 29177434 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 80 mg/m2 administered weekly on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 71
Study 29177434 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AZD4547 and paclitaxel
Number of subjects: 71
Study 25528898 — intervention group
Group type: EXPERIMENTAL
Intervention: ESL 1,200 mg
Number of subjects: 653
Study 25528898 — intervention group
Group type: EXPERIMENTAL
Intervention: ESL 800 mg
Number of subjects: 653
Study 25528898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 653
Study 23450315 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered Epworth Sleepiness Scale (ESSs)
Number of subjects: 225
Study 23450315 — intervention group
Group type: COMPARATOR
Intervention: Physician-administered Epworth Sleepiness Scale (ESSp)
Number of subjects: 225
Study 21505942 — intervention group
Group type: EXPERIMENTAL
Intervention: Possession of a bonus booklet (BB)
Number of subjects: 242
Study 21505942 — intervention group
Group type: COMPARATOR
Intervention: Residents without a bonus booklet (BB)
Number of subjects: 242
Study 19755930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-mediated immunity (CMI) to diphtheria and tetanus toxoids and acellular pertussis antigens
Number of subjects: 167
Study 19755930 — intervention group
Group type: EXPERIMENTAL
Intervention: Proliferative response to vaccine antigens
Number of subjects: 167
Study 19755930 — intervention group
Group type: EXPERIMENTAL
Intervention: CMI presence
Number of subjects: 167
Study 17695378 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of intraventricular hemorrhage (IVH) in patients with SAH
Number of subjects: 3539
Study 17695378 — intervention group
Group type: COMPARATOR
Intervention: Absence of intraventricular hemorrhage (IVH) in patients with SAH
Number of subjects: 3539
Study 15188169 — intervention group
Group type: COMPARATOR
Intervention: High-dose interferon alpha (9 million units)
Number of subjects: 36
Study 15188169 — intervention group
Group type: COMPARATOR
Intervention: Low-dose interferon alpha (3 million units)
Number of subjects: 36
Study 15188169 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study 11473558 — intervention group
Group type: EXPERIMENTAL
Intervention: s-ketamine (0.5 mg kg‐1)
Number of subjects: 90
Study 11473558 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 90
Study 11473558 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (1.5 microg kg‐1)
Number of subjects: 90
Study 11367689 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant alpha-2a interferon (1 million units daily for 6 days)
Number of subjects: 74
Study 11367689 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B12 and Vitamin B1 (conventional dose for 6 days)
Number of subjects: 74
Study 7836525 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted micromanipulation (Er:YAG laser)
Number of subjects: 0
Study 7836525 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching (Er:YAG laser)
Number of subjects: 0
Study 3415884 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 5 ml in sitting position
Number of subjects: 40
Study 3415884 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 5 ml in lateral position
Number of subjects: 40
Study 3415884 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric solution in sitting position
Number of subjects: 40
Study 3415884 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric solution in lateral position
Number of subjects: 40
Study 28873511 — intervention group
Group type: EXPERIMENTAL
Intervention: UC‐MSCs (1×10^6 UC‐MSCs/kg, four peripheral intravenous infusions, one infusion per week)
Number of subjects: 82
Study 28873511 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 82
Study 27029459 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-50% N2 O + i.v. remifentanil 0.1 μg/kg/min
Number of subjects: 21
Study 27029459 — intervention group
Group type: COMPARATOR
Intervention: remifentanil 0.1 μg/kg/min
Number of subjects: 21
Study 24941840 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenkangling Decoction + Western medicine
Number of subjects: 65
Study 24941840 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 65
Study 23234378 — intervention group
Group type: EXPERIMENTAL
Intervention: Information, motivation and behavioural skills (IMB) model intervention at School 1
Number of subjects: 259
Study 23234378 — intervention group
Group type: COMPARATOR
Intervention: Control group at School 2
Number of subjects: 259
Study 19548899 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision plus postoperative immunostimulation for 30 days with a natural product (STET)
Number of subjects: 261
Study 19548899 — intervention group
Group type: COMPARATOR
Intervention: Surgical excision alone (control group)
Number of subjects: 261
Study 18482822 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoelectric smoke alarms
Number of subjects: 643
Study 18482822 — intervention group
Group type: COMPARATOR
Intervention: Ionizing smoke alarms
Number of subjects: 643
Study 18482822 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium batteries
Number of subjects: 643
Study 18482822 — intervention group
Group type: COMPARATOR
Intervention: Carbon-zinc batteries
Number of subjects: 643
Study 16454441 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/d)
Number of subjects: 114
Study 16454441 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d)
Number of subjects: 114
Study 16454441 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg/d)
Number of subjects: 114
Study 16454441 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 114
Study 15060505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine plus caffeine (25 mg ephedrine, 200 mg caffeine)
Number of subjects: 16
Study 15060505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine alone (25 mg)
Number of subjects: 16
Study 15060505 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine alone (200 mg)
Number of subjects: 16
Study 15060505 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg) compared with ephedrine (25 mg)
Number of subjects: 16
Study 15060505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11011909 — intervention group
Group type: EXPERIMENTAL
Intervention: sibutramine plus orlistat
Number of subjects: 34
Study 11011909 — intervention group
Group type: COMPARATOR
Intervention: sibutramine plus placebo
Number of subjects: 34
Study 9362403 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose conjugated estrogen (1.25 mg)
Number of subjects: 8
Study 9362403 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose conjugated estrogen (10 mg)
Number of subjects: 8
Study 9362403 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 8
Study 1543426 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (20mg for one week after titration)
Number of subjects: 30
Study 3986438 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional intervention
Number of subjects: 89
Study 3986438 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-professional intervention
Number of subjects: 89
Study 3986438 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study 3286657 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine
Number of subjects: 0
Study 3286657 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31029069 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous PCI/CEA/CABG
Number of subjects: 43
Study 31029069 — intervention group
Group type: COMPARATOR
Intervention: Synchronous CEA/CABG
Number of subjects: 43
Study 28622115 — intervention group
Group type: EXPERIMENTAL
Intervention: Kochujang (32g/day)
Number of subjects: 60
Study 28622115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25160844 — intervention group
Group type: EXPERIMENTAL
Intervention: ULLS + EX (10 days of ULLS plus aerobic and resistance training)
Number of subjects: 19
Study 25160844 — intervention group
Group type: EXPERIMENTAL
Intervention: ULLS + EX
Number of subjects: 19
Study 25160844 — intervention group
Group type: COMPARATOR
Intervention: ULLS
Number of subjects: 19
Study 23839316 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Airtraq(R)
Number of subjects: 34
Study 23839316 — intervention group
Group type: COMPARATOR
Intervention: Conventional laryngoscope
Number of subjects: 34
Study 21718212 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 189
Study 21718212 — intervention group
Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 189
Study 21718212 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (non-switched)
Number of subjects: 189
Study 21718212 — intervention group
Group type: COMPARATOR
Intervention: Desipramine (non-switched)
Number of subjects: 189
Study 21718212 — intervention group
Group type: EXPERIMENTAL
Intervention: Switched patients (citalopram-desipramine and desipramine-citalopram)
Number of subjects: 189
Study 19486341 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee (100 mg caffeine)
Number of subjects: 12
Study 19486341 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 12
Study 16982783 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole as NanoCrystal formulation (NCF) 100 mg
Number of subjects: 0
Study 16982783 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole as NanoCrystal formulation (NCF) 300 mg
Number of subjects: 0
Study 16982783 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole as NCF (200 mg)
Number of subjects: 0
Study 16982783 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyitraconazole as NCF
Number of subjects: 0
Study 16982783 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole as HPBCD solution (200 mg)
Number of subjects: 0
Study 11966762 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium (200 microg) and Copper (3.0 mg) supplementation for 12 weeks
Number of subjects: 40
Study 11966762 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper (3.0 mg) supplementation for 12 weeks
Number of subjects: 40
Study 11966762 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium (200 microg) supplementation for 12 weeks
Number of subjects: 40
Study 11966762 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.394 g lactose)
Number of subjects: 40
Study 10088136 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.5 and 2 micrograms/kg, orally)
Number of subjects: 0
Study 10088136 — intervention group
Group type: EXPERIMENTAL
Intervention: THA (25 and 50 mg, orally)
Number of subjects: 0
Study 10150323 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Number of subjects: 235
Study 10150323 — intervention group
Group type: COMPARATOR
Intervention: Oral amitriptyline
Number of subjects: 235
Study 1704168 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 300 mg b.i.d.
Number of subjects: 12
Study 1704168 — intervention group
Group type: COMPARATOR
Intervention: Quinidine slow-release 800 mg b.i.d.
Number of subjects: 12
Study 373262 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldactone pro injectione (spironolactone)
Number of subjects: 30
Study 31642087 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally informed education program to increase cultural competence in emergencies
Number of subjects: 200
Study 31642087 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 200
Study 30093510 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical cystectomy with intracorporeal reconstruction (iRARC)
Number of subjects: 320
Study 30093510 — intervention group
Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC)
Number of subjects: 320
Study 27035460 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetically guided ultrasound (MGU) system
Number of subjects: 2
Study 27035460 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasound (CU)
Number of subjects: 2
Study 25019112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical brushing method
Number of subjects: 49
Study 25019112 — intervention group
Group type: COMPARATOR
Intervention: Horizontal brushing method
Number of subjects: 49
Study 23738508 — intervention group
Group type: EXPERIMENTAL
Intervention: SYKFT plus irbesartan (SI regimen)
Number of subjects: 80
Study 23738508 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus irbesartan (PI regimen)
Number of subjects: 80
Study 20598989 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW-INR group (target INR 1.5-2.5)
Number of subjects: 396
Study 20598989 — intervention group
Group type: COMPARATOR
Intervention: CONVENTIONAL-INR group (target INR 2.0-3.0)
Number of subjects: 396
Study 18203083 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contour tonometry (DCT)
Number of subjects: 50
Study 18203083 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometry (GAT)
Number of subjects: 50
Study 17067504 — intervention group
Group type: COMPARATOR
Intervention: Non-fractionated heparin (nFH) at 5-7 U/kg/hour
Number of subjects: 389
Study 17067504 — intervention group
Group type: COMPARATOR
Intervention: Epoprostenol at 4-5 ng/kg/min
Number of subjects: 389
Study 17067504 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy of epoprostenol and nFH at 2.5 U/kg/hour
Number of subjects: 389
Study 14575583 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (50 Gy) in the supraclavicular area and/or internal mammary area
Number of subjects: 162
Study 14575583 — intervention group
Group type: COMPARATOR
Intervention: Control group (no radiotherapy)
Number of subjects: 162
Study 14575583 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (50 Gy) in patients with LN(+) >= 4
Number of subjects: 162
Study 14575583 — intervention group
Group type: COMPARATOR
Intervention: Control group (no radiotherapy) in patients with LN(+) >= 4
Number of subjects: 162
Study 11281369 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 15 mg per day
Number of subjects: 9